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ril 22, 2013.he aim of this study was to determine whether use of an alternative ankle-brachial index (ABI) calculation method
improves mortality risk prediction compared with traditional methods.Background The ABI is used to diagnose peripheral arterial disease (PAD) and to identify those at risk for cardiovascular events.
Traditionally, the ABI is calculated with the higher of the dorsalis pedis and posterior tibial ankle arteries. Studies
directly comparing calculation methods are limited.Methods The ABI was calculated at baseline in 1,413 study participants undergoing nonemergent coronary angiography
subsequently followed for all-cause and cardiovascular mortality. There were 224 individuals assigned to the
traditional-PAD group (ABI <0.90) with the traditional ABI method. Of those remaining, an alternative ABI method
using the lower of the 2 ankle pressures assigned 282 patients to the alternative-PAD group. The 862 individuals not
assigned to PAD by either method were the no-PAD group.Results There were 163 mortalities during a median follow-up of 5.0 years. Adjusted Cox regression models showed that the
alternative-PAD group had an increased risk for all-cause (hazard ratio [HR]: 1.49; 95% conﬁdence interval: 1.01 to
2.19) and cardiovascular mortality (HR: 3.21; 95% conﬁdence interval: 1.53 to 6.37) versus the no-PAD group.
Additionally, in the no-PAD group, there was an 11% (HR: 1.11; 95% conﬁdence interval: 1.05 to 1.17) increased risk
of all-cause mortality/1-mm Hg increased difference between the left and right brachial systolic pressures.Conclusions The implementation of an alternative ABI method and use of the brachial difference identiﬁes individuals at an
increased risk for mortality who are currently missed with traditional ABI methods. Current ABI protocols might need
to be evaluated. (J Am Coll Cardiol 2013;62:553–9) ª 2013 by the American College of Cardiology FoundationSee page 560Peripheral arterial disease (PAD) results from atherosclerosis
and narrowing of the arteries in the distal extremities. Esti-
mates of PAD prevalence demonstrate a wide range, from
4% in general populations to 30% among primary care
practices (1,2). Individuals with PAD are at an increased risk
for myocardial infarction, aortic aneurysm rupture, ischemia,
and amputation (3) with a 6-fold increased risk of death from
cardiovascular causes (4,5). This cardiovascular morbidity
and mortality has been demonstrated even in PAD patients
without clinical symptoms (4). Although aggressive medical
treatment of PAD has been shown to reduce cardiovascular
morbidity and mortality, many patients are not recognized
and, as a result, are not adequately treated (2,6).lar Medicine, Stanford University School of
ena and Michael A. Wiener Cardiovascular
icine, New York, New York; and the zDivision
sity School of Medicine, Stanford, California.
e National Institutes of Health (K12HL087746
t Association (10BGIA3290011 to Dr. Leeper).
have no relationships relevant to the contents
13; revised manuscript received April 7, 2013,The ankle-brachial index (ABI) provides an objective
clinical measure for the diagnosis of PAD, with normal ABI
deﬁned as at least 1.00 to 1.40 and PAD classiﬁed as an ABI
of<0.90. These criteria have been validated against peripheral
angiography to calculate the sensitivity and speciﬁcity of the
ABI as a diagnostic tool for PAD.Although the speciﬁcity has
been shown to be reproducibly high (>95%) (7–10), some
validation studies have demonstrated low sensitivity (7,8).
Therefore, methods to improve the sensitivity of the ABI,
without a concomitant reduction in speciﬁcity, might improve
risk prognostication.According to current guidelines and a recent Scientiﬁc
Statement from the American Heart Association (11), the
preferred method to calculate the ABI requires measuring the
systolic pressures of the left and right brachial arteries in
addition to the dorsalis pedis and posterior tibial arteries in
each leg. Then, for each leg, the higher of the dorsalis pedis and
posterior tibial pressures is divided by the higher brachial
pressure, and the lower overall ABI of the 2 legs is used to
determine PAD status. Here we assess the implementation of
Figure 1 ABI and Brachial
ABI ¼ ankle-brachial index; BD ¼ br
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554an alternative measure of ABI, by
instead using the lower of the
dorsalis pedis and posterior tibial
pressures and examine whether
individuals reclassiﬁed into the
PAD group with this alternative
measure are at an increased risk of
mortality. Additionally, we deter-
mine whether there is evidence
to support the direct evaluation of
the brachial difference in risk pre-
diction among individuals under-
going ABI testing.Methods
Study population. The GenePAD (Genetic Determinants
of Peripheral Arterial Disease) study comprises individuals
(n¼ 1,755)who underwent an elective, nonemergent coronary
angiogram for angina, shortness of breath, or an abnormal
stress test at Stanford University and Mount Sinai Medical
Centers between January 1, 2004, and March 1, 2008, as
previously described (12–14).
Inclusion criteria. Participants were included in the study
sample if complete data were available on all covariates
(n ¼ 1,413). Individuals without both a dorsalis pedis and
posterior tibial systolic pressure recorded in at least 1 leg were
excluded (n ¼ 5), because calculation of both a traditional
and alternative ABI value would not be possible. Remaining
eligible patients with an ABI >1.40 were excluded (n ¼ 40)
(15). With these criteria, 1,368 patients were included.
Outcomes. The outcomes of interest in this analysis were
death from any cause and death from cardiovascular causes
including myocardial infarction, cardiac arrest, stroke, heartDifference Calculations
achial difference; DP ¼ dorsalis pedis artery; PT ¼ pfailure, or aneurysm rupture. Ascertainment of mortality and
cause of death was achieved through phone or postal
communication, medical record review, and the Social
Security Death Index. New mortalities were identiﬁed
through March 31, 2012.
Covariates. The use of lipid-lowering and anti-hypertensive
medications was evaluated by direct medication inventory.
Diabetes status was classiﬁed as self-reported use of insulin
or oral hypoglycemic agents. Hypertension was deﬁned as
a systolic blood pressure of 160 mm Hg or use of anti
hypertensive medications. Creatinine and total and high-
density lipoprotein (HDL) cholesterol levels were measured
at the time of coronary angiography. An experienced car-
diologist who was blinded to participant details evaluated
coronary angiograms. Hemodynamically signiﬁcant coronary
artery disease (CAD) was deﬁned as >60% stenosis (16,17).
ABI calculations. Before the coronary angiogram, poste-
rior tibial, dorsalis pedis, and brachial artery systolic pres-
sures were measured with a 5-MHz Doppler ultrasound.
Calculation of the ABI with the traditional and alternative
methods is illustrated in Figure 1. The traditional ABI was
calculated for each leg by dividing the higher of the posterior
tibial or dorsalis pedis pressures by the higher of the left or
right brachial systolic pressures. Then, the leg with the lower
ABI measurement was recorded as the traditional ABI value.
The alternative ABI was calculated for each leg by dividing
the lower of the posterior tibial or dorsalis pedis pressures by
the higher of the left or right brachial systolic pressures.
Then, the leg with the lower ABI measurement was recor-
ded as the alternative ABI value. For each method the index
leg was deﬁned as the leg with the lower ABI, and data from
the contralateral leg were not included in the analysis.
PAD group classiﬁcation. Study participant classiﬁcation
into mutually exclusive groups is represented in Figure 2.osterior tibial artery.
Figure 2 Study Participant PAD Group Classiﬁcations
Traditional ankle-brachial index (ABI) refers to the method using the higher of the
dorsalis pedis and posterior tibial pressures, whereas alternative ABI refers to the
method using the lower of the dorsalis pedis and posterior tibial pressures. PAD ¼
peripheral arterial disease.
Table 1 Index Leg ABI Values
Higher ABI Lower ABI
No-PAD 1.10  0.09 (1.02–1.16) 1.02  0.08 (0.95–1.07)
Traditional-PAD 0.71  0.16 (0.60–0.84) 0.65  0.19 (0.54–0.81)
Alternative-PAD 1.02  0.10 (0.94–1.07) 0.81  0.11 (0.77–0.88)
Values are mean  SD (interquartile range).
ABI ¼ ankle-brachial index; IQR ¼ interquartile range; PAD ¼ peripheral arterial disease.
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555Patients with an ABI of <0.90 in either leg with the
traditional method were classiﬁed as having traditional-
PAD. Of those remaining (who therefore had an ABI
of 0.90 in both legs with the traditional method), indi-
viduals with an ABI of <0.90 in either leg with the alter-
native method were classiﬁed as having alternative-PAD.
Patients without PAD as classiﬁed by either method were
used as the no-PAD reference group. Among individuals in
the no-PAD group, we calculated the brachial difference as
the difference between the left and right brachial systolic
pressures.
Statistical methods. Baseline patient characteristics were
calculated for the 3 PAD status groups and compared with
a t test or chi-square test. For all survival analyses, the follow-
up time was deﬁned as the period between the enrollment
interview and the last conﬁrmed follow-up or date of death.
Hazard ratios (HRs) were calculated with adjusted Cox
proportional hazard models to compare all-cause and cardio-
vascular mortality risk in the traditional-PAD, alternative-
PAD, and no-PAD groups. Additionally, individuals with
severely decreased ABI values of<0.40 have been shown to be
at a further increased risk for PAD-related sequelae (18). To
examine the ability of the alternative ABI method to stratify
mortality risk, we compared the risk of individualswith severely
decreased ABIs with the traditional method with the risk of
any individual in the full study cohort with an ABI<0.40 only
with the application of the alternative method. Similarly, we
compared the risk of individuals with mildly to moderately
decreased ABIs (0.40 ABI <0.90) with the traditionalmethod with the risk of individuals with moderately decreased
ABIs only when using the alternative method. All survival
analyses were adjusted for age, sex, race, smoking history (ever
or never), BMI, hypertension, use of lipid-lowering medica-
tions at enrollment, diabetes, total cholesterol, HDL choles-
terol, creatinine and CAD. Proportional-hazards assumptions
were evaluated by Schoenfeld’s residuals tests.
Next, we calculated the C-index to quantify the integrated
sensitivity and speciﬁcity of the traditional- and alternative-
PAD classiﬁcations in predicting all-cause and cardiovas-
cular mortality. Therefore, the traditional and alternative
ABI methods were separately applied to the full study cohort
to ascertain the respective discriminatory capacity of each
method in all comers. In survival analysis, the C-index
interpretation is equivalent to the area under the ROC curve
or c-statistic, while allowing for censored data (19).
We further examined whether the brachial difference
provided additional prognostic information in predicting
mortality risk among those with no detectable PAD by either
the traditional or alternative method. This variable was
calculated as the difference between the left and right brachial
systolic pressures and examined as a continuous variable and
as a binary variable of <10 mm Hg or 10 mm Hg. The
brachial difference was calculated in 200 patients in the no-
PAD group after excluding individuals with only 1 brachial
pressure due to intravenous placement or amputation.
Tests were considered signiﬁcant if the 2-sided p value
was <0.05. All analyses were performed with Stata (version
12.0, StataCorp, College Station, Texas). Study data were
collected and managed with REDCap electronic data
capture tools hosted at Stanford University (20).Results
Study population characteristics. There were 224 indi-
viduals in the traditional-PAD group, which consisted of
those categorized as having PAD (ABI <0.90) with the
traditional ABI method. Among those remaining, the al-
ternative ABI method placed 282 individuals into the
alternative-PAD group. The no-PAD group consisted of the
remaining 862 participants not classiﬁed as having PAD with
the traditional or alternative ABI methods. The mean higher
and lower ABI for the index leg in each group is presented in
Table 1. The prevalence of PAD when applying each
method to the full study cohort was 16.4% for the traditional
ABI method and 37.0% for the alternative ABI method.
There were 163 mortalities (12%), of which 47 were known
Table 2 Baseline Study Population Characteristics by PAD Status
Characteristic
Traditional-PAD
(n ¼ 224)
Alternative-PAD
(n ¼ 282)
No-PAD
(n ¼ 862)
p Value, trad
vs. alt
p Value, trad
vs. no-PAD
p Value, alt
vs. no-PAD
Age, yrs 71  9 69  10 65  10 0.002 <0.001 <0.001
Female 107 (48) 107 (38) 254 (29) 0.026 <0.001 0.008
Ethnicity
Caucasian 118 (53) 151 (54) 500 (58) 0.846 0.152 0.189
African 43 (19) 35 (12) 81 (9) 0.036 <0.001 0.145
Hispanic 30 (13) 33 (12) 88 (10) 0.567 0.172 0.479
Asian 11 (5) 26 (9) 74 (9) 0.064 0.068 0.743
Other* 22 (10) 37 (13) 119 (14) 0.251 0.114 0.771
Hypertensive 197 (88) 230 (82) 666 (77) 0.049 <0.001 0.128
BMI, kg/m2 28  6 30  7 29  6 0.018 0.108 0.109
Lipids, mg/dl
Total cholesterol 145  40 137  37 137  36 0.028 0.004 0.910
HDL cholesterol 41  13 42  12 40  12 0.447 0.160 0.008
Ever smoker 149 (67) 160 (57) 482 (56) 0.025 0.004 0.809
Cholesterol-lowering medication 179 (81) 223 (80) 668 (78) 0.766 0.285 0.428
Clopidogrel 91 (41) 100 (36) 263 (31) 0.225 0.003 0.113
Diabetic 101 (45) 88 (31) 225 (26) 0.001 <0.001 0.095
Coronary artery disease 197 (88) 215 (76) 621 (72) 0.001 <0.001 0.168
Creatinine, mg/dl 1.4  1.5 1.1  0.3 1.2  1.0 <0.001 0.002 0.059
Values are mean  SD or n (%). N ¼ 1,368. *Includes Asian-Indian, Pakistani, Middle Eastern, and Paciﬁc Islander.
Alt ¼ alternative; BMI ¼ body mass index; HDL ¼ high-density lipoprotein; PAD ¼ peripheral arterial disease; trad ¼ traditional.
Table 3
HRs for Association of PAD Status With
Mortality Outcomes
HR (95% CI) p Value
p Value for
Difference
All-cause mortality
No-PAD ref (1.0) ref
Traditional-PAD 1.72 (1.17–2.54) 0.006
0.506
Alternative-PAD 1.49 (1.01–2.19) 0.046
Cardiovascular mortality
No-PAD ref (1.0) ref
Traditional-PAD 2.64 (1.25–5.56) 0.011
0.653
Alternative-PAD 3.21 (1.53–6.37) 0.002
Adjusted for age, sex, race, smoking history, body mass index, hypertension, use of lipid-lowering
medication, diabetes, total cholesterol, HDL cholesterol, coronary artery disease, and creatinine.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; PAD ¼ peripheral arterial disease; ref ¼ reference.
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556to be from cardiovascular causes, during a median follow-up
period of 5.0 years (interquartile range: 4.0 to 6.3 years).
Enrollment characteristics of the 1,368 participants in this
study according to PAD status are displayed in Table 2. The
alternative-PAD group signiﬁcantly differed from the
traditional-PAD group with a lower mean age, lower total
cholesterol and creatinine levels, and a signiﬁcantly lower
proportion of hypertensive individuals, smokers, diabetic
individuals, and individuals with CAD. Conversely, the only
signiﬁcant differences observed between the alternative-
PAD group as compared with the no-PAD group were
a higher mean age, higher HDL cholesterol, and a greater
proportion of women.
For all-cause and cardiovascular mortality, individuals in
the traditional-PAD group had signiﬁcantly increased risk
compared with those in the no-PAD group (Table 3).
Individuals in the alternative-PAD group (who would have
been considered “normal” by the traditional ABI method)
also had signiﬁcantly elevated risk compared with the no-
PAD group. Notably, the estimated risk in the traditional-
and alternative-PAD groups were equally elevated and did
not signiﬁcantly differ from each other for either all-cause
(p ¼ 0.506) or cardiovascular mortality (p ¼ 0.653).
Patients with a severely decreased ABI (<0.40) with the
traditional ABI method as well as those with an ABI <0.40
only when using the alternative method had a >3-fold
increased risk for all-cause mortality (Table 4). This risk
did not signiﬁcantly differ between ABI calculation
methods (p ¼ 0.712). Similarly, patients placed in the mild/
moderate ABI category (0.40 ABI <0.90) with the
traditional method and individuals moved into this group
only with the application of the alternative method were ata signiﬁcantly increased risk for death from any cause with
an HR that did not statistically differ between these 2
groups (p ¼ 0.618).
We then directly compared the discriminatory capacity of
the traditional and alternative ABI methods among the
entire cohort. The C-index demonstrated that there was no
loss of integrated sensitivity and speciﬁcity in predicting all-
cause or cardiovascular mortality with the implementation of
the alternative ABI method to designate PAD status as
compared with the traditional method among all comers
(Table 5). Because the cardiovascular mortality event
rate was so high among those in the alternative-PAD
group (Table 3) and they would have been inappropriately
classiﬁed as low-risk with the traditional method, the clas-
siﬁcation of PAD with the alternative ABI method resulted
in a signiﬁcantly greater C-index for cardiovascular mortality
Table 4 Adjusted HRs for Association of ABI Severity Status With All-Cause Mortality
HR (95% CI) p Value p Value for Difference
Severe (ABI <0.4)
No-PAD (n ¼ 862) ref (1.0) ref
With traditional ABI method (n ¼ 11) 4.13 (1.57–10.90) 0.004
0.618
Only when using alternative ABI method (n ¼ 30) 3.13 (1.59–6.16) 0.001
Mild/moderate (0.4  ABI <0.9)
No-PAD (n ¼ 862) ref (1.0) ref
With traditional ABI method (n ¼ 213) 1.61 (1.08–2.41) 0.020
0.712
Only when using alternative ABI method (n ¼ 280) 1.48 (1.00–2.19) 0.049
Adjusted for age, sex, race, smoking history, body mass index, hypertension, use of lipid-lowering medication, diabetes, total cholesterol, HDL
cholesterol, coronary artery disease and creatinine.
Abbreviations as in Tables 1 and 3.
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CAD status (p ¼ 0.021).
Among the no-PAD group, who would be classiﬁed as
lowest risk with both ABI methods, we found that the
brachial difference predicted an 11% (95% conﬁdence interval:
1.05 to 1.17; p < 0.001) increase in all-cause mortality
risk/1-mm Hg difference between the left and right brachial
systolic pressures (n ¼ 200). Furthermore, individuals with
a brachial difference of at least 10 mm Hg (n ¼ 16)
demonstrated a nearly 4-fold increased risk of all-cause
mortality compared with those with a brachial difference
of <10 mm Hg (HR: 3.96; 95% conﬁdence interval: 1.21 to
13.02; p ¼ 0.023).
The risk of all-cause and cardiovascular mortality did not
signiﬁcantly differ between participants excluded (n ¼ 387)
and included (n ¼ 1,368) in the study-cohort, and tests for
interaction showed that the reported results were not
signiﬁcantly different according to sex or racial group. Sen-
sitivity analyses adjusting for clopidogrel and, separately,
removing heart failure and aneurysm rupture as causes of
cardiovascular mortality, yielded results consistent with our
primary data. Schoenfeld’s residuals tests demonstrated that
the proportional hazards assumption was met for all models.
Discussion
The ABI is a validated and widely used measure to detect the
presence of PAD. Currently, the ABI is recommended as the
ﬁrst-line test for the diagnosis of PAD among individuals
with symptoms and clinical ﬁndings suggestive of PAD (11).Table 5
C-Index for PAD Status Classiﬁed With Traditional and
Alternative ABI Methods
C-index (95% CI) p Value p Value for Difference
All-cause mortality
Traditional-PAD 0.570 (0.534–0.606) <0.001 0.150
Alternative-PAD 0.596 (0.555–0.636) <0.001
Cardiovascular
mortality
Traditional-PAD 0.575 (0.508–0.641) <0.001 0.013
Alternative-PAD 0.665 (0.595–0.734) <0.001
The PAD indicates an ABI <0.9 by the stated method.
Abbreviations as in Tables 1 and 3.Because PAD is considered a coronary heart disease risk
equivalent (21), the ABI is also a simple tool that can identify
those at risk of major adverse cardiovascular events (MACE).
The current methods used to identify the presence or absence
of PAD rely on criteria that might be insensitive (7,8) and
have been suggested to falsely classify some at-risk individ-
uals as “normal.” In this study, we compared participants
classiﬁed as having PAD (ABI <0.90) with the traditional
ABI calculation method with patients that were classiﬁed as
having PAD only when using an alternative ABI calculation
method, to see whether we could enhance the prognostic
utility of this widely used test.
Individuals who were reclassiﬁed as having PAD only
when implementing the alternative ABI calculation had
a mortality risk that was signiﬁcantly greater than those
without PAD by either method. This is important, because
these patients would normally be classiﬁed as “free-of-
disease” and would not meet criteria to have risk-reducing
therapies initiated. Additionally, the risk in this alternative
group was as high as the risk for those individuals classiﬁed
as having PAD with the traditional ABI method. These
ﬁndings were consistent for both all-cause and cardiovas-
cular mortality as well as when examining categories of ABI
severity. Finally, among those without PAD detected by
either ABI method, the brachial difference was a signiﬁcant
predictor of all-cause mortality risk, which is consistent with
previous studies demonstrating an association between
increased brachial difference and markers of subclinical
atherosclerosis (22). This ﬁnding emphasizes that vascular
disease in any anatomic distribution might provide impor-
tant prognostic information and should not be ignored.
Although a similarly increased risk of mortality was
demonstrated for the traditional- and alternative-PAD
groups compared with the no-PAD group, examination of
baseline characteristics revealed that the alternative-PAD
group had far fewer established cardiovascular risk factors,
such as signiﬁcantly lower rates of hypertension, smoking,
diabetes, and CAD, than the traditional-PAD group. This is
an important ﬁnding, because their pre-test probability of
disease is low, and it is probable that a “normal” traditional
ABI would lead many practitioners to “rule-out” disease,
according to Bayesian principles. It is unclear why individuals
Nead et al. JACC Vol. 62, No. 6, 2013
Alternate Ankle-Brachial Index and Mortality August 6, 2013:553–9
558in this group resemble lower-risk individuals and harbor
disease in an alternative anatomic pattern, but it is clear that
their risk is signiﬁcantly elevated and that they are often
clinically ignored. Future studies are required to understand
whether these individuals possess other unmeasured risk
factors (e.g., premature endothelial dysfunction) that accel-
erate their risk of death or whether isolated/focal tibial
disease might reﬂect a more aggressive variant of PAD.
When applied to all-comers, the implementation of the
alternative ABI calculation method will often result in
a lower ABI value compared with the traditional method.
Therefore, a greater number of individuals will be classiﬁed
as having PAD with the alternative method, making it
a more sensitive predictor of risk. Although this study shows
that the use of the alternative method detects a group of
individuals at increased risk for mortality that was not
previously identiﬁed, we wished to determine whether the
implementation of this more sensitive measure in the full
study cohort resulted in a net loss of integrated sensitivity
and speciﬁcity for predicting MACE. We evaluated this
with the C-index, which provided evidence against any loss
of integrated sensitivity and speciﬁcity for all-cause
mortality. Indeed, because the risk of death was so high in
the alternative-PAD group, and this group was falsely
classiﬁed as normal by the traditional ABI method, we
found that the ability to predict future cardiovascular death
was signiﬁcantly increased when using the alternative ABI
method to deﬁne PAD status in the entire cohort. Thus, our
concern that re-deﬁning the interpretation of this test to
capture more at-risk individuals would enhance sensitivity at
an unacceptable cost in speciﬁcity (for MACE) seems
unfounded.
The current study differs from previous reports that
attempted to identify more sensitive methods to diagnose
PAD (23,24) or prognosticate the risk of future events (25).
Use of the lower ankle pressure in calculating the ABI has
been shown to predict a higher prevalence of PAD while
having greater sensitivity for atherosclerotic disease (23,24).
Although a recent American Heart Association Scientiﬁc
Statement does acknowledge that the lower ankle pressure
can be used as a prognostic marker for cardiovascular events,
it gives this approach a Level C recommendation and raises
concerns about “overdiagnosis” and “unnecessary tests” that
might be associated with less-speciﬁc ABI methods (11). To
our knowledge, only 1 previous study has examined the
implementation of this alternative ABI calculation in pre-
dicting clinical outcomes (25). Their study reported an
increased risk of cardiovascular events among those subjects
assigned to the “Suspected PAD” group by an alternative
ABI method, similar to the ﬁndings reported here. In
contrast to the current report, however, their study evaluated
a signiﬁcantly younger patient population with fewer
comorbidities and did not observe a statistically signiﬁcant
difference in risk for cardiovascular events (death from
cardiovascular causes, nonfatal myocardial infarction, or
nonfatal stroke) in fully adjusted Cox-regression models.These ﬁndings might be explained in part by the fact that
both the presence and systemic sequelae of PAD increase
signiﬁcantly with age and thus might not have been fully
manifest in the younger cohort from the prior study (26).
In the current report, the alternative method correctly
prognosticated risk after controlling for all comorbidities and
did so without a reduction in net sensitivity and speciﬁcity,
which has not been previously shown.
Recently published guidelines (11) for calculating the ABI
use the higher brachial pressure and higher of the dorsalis
pedis and posterior tibial pressures in each leg. The higher
brachial pressure is uniformly used to limit inaccurate ABI
calculations among individuals with lower brachial pressures
in 1 arm due to subclavian or axillary artery stenosis.
However, the rationale for using the higher ankle pressure is
less clear, and direct comparisons of different methods are
limited. It is obvious that single vessel coronary disease is
associated with cardiovascular events and mortality in CAD
(27) and that the severity of a stenosis does not always
predict the likelihood of future plaque rupture (28). It could
be argued that single vessel disease in the lower vasculature
should not be overlooked, as when using the higher ankle
pressure and dismissing the lower pressure recorded in
a potentially diseased vessel. Although concerns about
overdiagnosis, false positivity, and resource use with more
sensitive ABI methods are valid (11), consideration should
be given to the potential value of identifying at-risk indi-
viduals earlier in the disease process. The classical ABI is
currently recommended as the ﬁrst-line noninvasive test for
the diagnosis of suspected PAD as well as a screening test
for those considered to be at high risk for cardiovascular
disease (11). When taken in the context of prior studies (25),
the current ﬁndings suggest that the ABI interpreted with
the alternative method might have an additional role in the
risk stratiﬁcation of subjects with an indeterminate risk
proﬁle, such as patients with few comorbidities but symp-
toms severe enough to warrant cardiac catheterization.
Study limitations. The current study was undertaken in
a cohort of individuals undergoing coronary angiography
and might not be generalizable to other populations.
Additionally, we were unable to evaluate the accuracy of
PAD diagnosis with the traditional and alternative ABI
methods against a gold standard such as peripheral angi-
ography. Larger cohorts will be needed to conﬁrm the utility
of the alternative ABI method by ABI severity, because this
analysis had limited events within these subgroups. Addi-
tionally, future studies are needed to examine the additive
value of the alternative ABI method compared with estab-
lished risk models.
Conclusions
Peripheral arterial disease is associated with an increased risk
of MACE. The ABI is widely used to diagnose PAD and to
inform the medical management of patients. Here we show
that the implementation of an alternative ABI calculation
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increased risk for all-cause and cardiovascular mortality.
These individuals would not be identiﬁed with traditional
ABI methods and otherwise might be ignored due to their
clinical risk proﬁle. Additionally, we provide evidence that
the evaluation of the brachial difference among patients not
classiﬁed as having PAD might provide useful data for risk
prediction that is not directly evaluated under current
guidelines. These methods improved the prognostic utility
of the ABI without a net impairment in sensitivity and
speciﬁcity. These ﬁndings should be replicated in lower-risk
general populations, and randomized controlled trials will be
needed to determine whether the use of the lower ankle
pressure in ABI calculations improves clinical outcomes.
The results of this study suggest that protocols commonly
employed for this widely used diagnostic test might need to
be re-evaluated.
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